Nasdaq

This Antibiotic Biotech Is Out of Second Chances at Nasdaq

Lakewood-Amedex did a 1-for-10 reverse split in June. That split is now the reason Nasdaq will not give it the standard compliance period to fix its share price.

This Antibiotic Biotech Is Out of Second Chances at Nasdaq
Illustration: life sciences sector, not the company's own operations. Systec D-65 — SystecAutoclaves, CC BY-SA 4.0, via Wikimedia Commons.

On June 22, Lakewood-Amedex turned every ten of its shares into one. By November, that move had become the reason Nasdaq would not give the company a compliance period.

Lakewood-Amedex Biotherapeutics Inc. NASDAQ: LABT

Nasdaq's listing team sent a delisting notice on November 10, applying a rule that bars the standard compliance period for any company that has done a reverse split within the prior year. Lakewood-Amedex had done one that June. The stock had been below $1.00 for 30 consecutive business days — September 29 through November 9 — before the notice arrived.

That compliance period normally gives a company time to bring its price back above the minimum before trading is suspended. Here, the reverse split within the prior year had closed that path. Without a hearing request by November 17, trading was set to be suspended at the open of November 19.

Shares closed 15.03% higher at $0.2449, on dollar volume of about $14.8 million.

The company says it intends to request a hearing before a Nasdaq panel, which would pause the suspension while the panel reviews its case. At the hearing, it plans to present a plan to regain compliance — one the filing says may include a reverse split.

The filing says there is no assurance the panel will grant continued listing or that the company will regain compliance.

Written by the PennyStocks.News desk from company filings and releases. Figures as reported by the company; no guarantee of accuracy or completeness. Nothing here is investment advice.